$4.89
+0.34 (+7.47%)
Open$4.60
Previous Close$4.55
Day High$4.91
Day Low$4.54
52W High$16.45
52W Low$4.11
Volume—
Avg Volume444.6K
Market Cap190.40M
P/E Ratio—
EPS$-3.97
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+268.9% upside
Current
$4.89
$4.89
Target
$18.04
$18.04
$12.20
$18.04 avg
$27.27
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 23.93M | 42.90M | 41.05M |
| Net Income | -135,289,342 | 8.98M | 10.98M |
| Profit Margin | -565.5% | 20.9% | 26.8% |
| EBITDA | -144,750,952 | 15.57M | 16.71M |
| Free Cash Flow | — | 11.03M | 8.57M |
| Rev Growth | — | +8.9% | +15.8% |
| Debt/Equity | — | 0.18 | 0.20 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |